Spanish Cancer Institute Using Sysmex Inostics, Merck Serono Blood Dx to Study mCRC Personalized Rx | GenomeWeb

NEW YORK (GenomeWeb) – Vall d'Hebron's Institute of Oncology in Barcelona, Spain will be the first liquid biopsy testing center that will use Sysmex Inostics' OncoBEAM blood test as part of its research on RAS biomarkers in the context of personalizing treatments for metastatic colorectal cancer patients.

"This marks an important milestone in Sysmex Inostics' collaboration with … Merck Serono," the partners said in a statement announcing the adoption of the test by Vall D'Hebron.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.